Member Profile

Dr. Kathelijn Fischer

Kathelijn Fischer has been working at the University Medical Center Utrecht, both as a Paediatric Haematologist and a Clinical Epidemiologist.

Dr Fischer finished her medical training in 1988 is a registered paediatrician since 1994. Dr Fischer specialized in paediatric haematology and oncology in Utrecht, the Netherlands. Subsequently, she performed PhD research in haemophilia while training as a clinical epidemiologist. She published her thesis on ‘Treatment strategies in severe haemophilia: in search for the optimal treatment’ in 2001.

Dr Fischer supervises four PhD students and served as co-promotor for seven other PhD students in the field of haematology, neurology and gynaecology.

Dr Fischer is principal investigator in several international studies on long-term results of haemophilia treatment, and is the epidemiologist for the European Haemophilia Safety Surveillance Study (EUHASS-member of the steering committee) as well as for the European PedNet registry.

The specific areas of expertise and interest of dr Fischer include the epidemiology of haemophilia (including use of registries), prophylactic treatment, and outcome assessment in haemophilia care.

www.vancreveldkliniek.nl

Publications

May 20, 2021

Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database

Authors
Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG).
Citation
J Thromb Haemost. 2021 May 20. doi: 10.1111/jth.15395. Epub ahead of print. PMID: 34013558.
December 5, 2020

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

The 62nd ASH Annual Meeting and Exposition (Dec 5-8, 2020)
Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
December 5, 2020

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments.

The 62nd ASH Annual Meeting and Exposition (Dec 5-8, 2020)
Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K.
Citation
November 5, 2020

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
Blood 2020; 136 (S1): 22-23
November 5, 2020

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
Blood 2020; 136 (S1): 21-22.
May 22, 2020

Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an international prophylaxis study group global survey

Authors
Ignas DM, Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, Fischer K, Gibikote S, Keshava S, Querol F, Abad A, and Babyn P on behalf of the Ultrasound Taskforce of the Imaging Expert Working Group of the International Prophylaxis Study Group (IPSG)
Citation
Haemophilia 2020: 26 (4): 685 - 693
May 20, 2018

Use of ultrasound for assessment of musculoskeletal disease in persons with hemophilia: Results of an International Prophylaxis Study Group (IPSG) survey

The XXXI World Federation of Hemophilia Congress (May 20 - 24, 2018 – Glasgow, Scotland)
Authors
Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, Fischer K, Sridhar G, Shyamkumar K, Querol F, Babyn P
Citation
May 10, 2018

Use of ultrasound for assessment of musculoskeletal disease in persons with hemophilia: Results of an International Prophylaxis Study Group (IPSG) survey.

Authors
Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, Fischer K, Sridhar G, Shyamkumar K, Querol F, Babyn P.
Citation
Haemophilia 2018; 24 (S5): 391, W- P- 085